In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

First quarter sales jumped 80% to $1.8 mil. due to higher skin care sales and licensing royalties, Kinetin manufacturer says. Company records a net loss of $593,000 compared to deficit of $1.4 mil. in prior-year period. Effort to focus on high-margin royalty income received from licenses led to improved results, Napa, Calif. firm maintains. Senetek licenses its Kinetin technology to Revlon and The Body Shop among other firms



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts